Therini Bio
Therini Bio is a clinical-stage biopharmaceutical company developing fibrin-targeting monoclonal antibodies to treat inflammatory neurological and retinal diseases, with lead candidate THN391 in Phase 1b trials for Alzheimer's Disease and Diabetic Macular Edema.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Therini Bio does
Therini Bio is a clinical-stage biopharmaceutical company developing fibrin-targeting immunotherapies for inflammatory neurological and retinal diseases. Founded in 2019 as MedaRed, Inc. (renamed Therini Bio in February 2020) based on pioneering research by Dr. Katerina Akassoglou at Gladstone Institutes and the University of California San Francisco, the company is headquartered in South San Francisco, California (with operations embedded in Eli Lilly's Gateway Labs) and is incorporated in Delaware.
The company's core technology centers on monoclonal antibodies that selectively block the inflammatory epitope of fibrin without disrupting its normal coagulation function, addressing chronic neuroinflammation and neuronal damage caused by vascular dysfunction. Its lead candidate, THN391, is a first-in-class humanized monoclonal antibody currently in Phase 1b trials for both Alzheimer's Disease (initiated July 2025) and Diabetic Macular Edema (initiated May 2026), supported by Phase 1a data demonstrating clean safety, no impact on coagulation, and a 40-50 day half-life supporting monthly dosing. A second program, THN622, is a bispecific anti-fibrin and anti-VEGF antibody selected as the lead retinal candidate in May 2026.
Therini Bio is pre-revenue and funds operations through venture capital and non-dilutive grants. The company has raised approximately $98 million across seed, seed extension, Series A, and Series A extension rounds from a top-tier syndicate including SV Health Investors, Dementia Discovery Fund, MRL Ventures (Merck), Sanofi Ventures, and Eli Lilly. The planned commercial model is traditional biopharmaceutical distribution through specialty, hospital, and retail pharmacies serving neurology and ophthalmology prescribing channels following regulatory approval.
Therini Bio firmographics
Firmographics- Name
- Therini Bio
- Legal name
- Therini Bio, Inc.
- Website
- https://therinibio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Therini Bio is a clinical-stage biopharmaceutical company developing fibrin-targeting monoclonal antibodies to treat inflammatory neurological and retinal diseases, with lead candidate THN391 in Phase 1b trials for Alzheimer's Disease and Diabetic Macular Edema.
- Ownership category
- akta.pro rank
Therini Bio industry classification
Industry- Product category
- Neuroscience Biopharmaceuticals
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industries
- Neurology/CNS Gene Therapies (HLAAACAH), Ophthalmology Gene Therapies (HLAAACAG)
Keywords
Where Therini Bio is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Therini Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Biopharmaceutical Product Revenue: Pre-revenue clinical-stage company. Plans to commercialize fibrin-targeting therapies (THN391, THN622) for neurodegenerative and retinal diseases upon regulatory approval. Revenue expected from product sales through traditional pharmaceutical distribution channels.
Go-to-market motion1 record
Marketing channels4 records
Therini Bio product offering
Product offeringCore offering
Therini Bio is developing a clinical-stage pipeline of fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. The company's lead candidate THN391 is a first-in-class humanized monoclonal antibody that selectively blocks the inflammatory epitope of fibrin without affecting coagulation, being advanced through Phase 1b trials for Alzheimer's Disease and Diabetic Macular Edema. The pipeline also includes THN622, a bispecific antibody combining anti-fibrin and anti-VEGF mechanisms for retinal conditions.
Product overview
Therini Bio is developing a clinical-stage pipeline of fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. The core portfolio consists of THN391, a first-in-class humanized monoclonal antibody targeting fibrin inflammatory epitope for Alzheimer's Disease and Diabetic Macular Edema, currently in Phase 1b clinical trials. The pipeline also includes THN622, a bispecific antibody combining anti-fibrin and anti-VEGF mechanisms for retinal conditions. The company leverages pioneering science from Dr. Katerina Akassoglou's laboratory at Gladstone Institutes and UCSF.
Differentiator
Problem solved
Functional benefit
Products and services
- THN391
- THN622
Quantifiable outcome
- Phase 1a trial: THN391 was well-tolerated with no Serious Adverse Events reported in healthy volunteers
- +5 more outcomes
Companies that use Therini Bio
Customer profileSegments3 records
Ideal customer profiles2 records
Therini Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Therini Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Gladstone InstitutescoreLicensed foundational technology from Dr. Katerina Akassoglou's laboratory at Gladstone Institutes at UC San Francisco. Dr. Akassoglou serves as Scientific Founder and Scientific Advisor. The discovery of fibrin's role in neurological diseases originated from Gladstone research.
- University of California San Francisco (UCSF)coreDr. Katerina Akassoglou is Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF. Technology licensed from UCSF and formerly UC San Diego.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Therini Bio competitors and assessment
Company assessmentDirect peers
- Opthea Limited: Clinical-stage biotech developing novel therapies for retinal diseases including DME. Joel Naor was previously CMO at Opthea overseeing its Phase 3 program. Direct overlap on DME indication.
- Alector: Clinical-stage biotech developing monoclonal antibody immunotherapies for neurodegenerative diseases including Alzheimer's and frontotemporal dementia. Directly comparable therapeutic modality, target indications, and clinical stage, with major pharma partnerships (GSK, AbbVie).
- Prothena Corporation: Public clinical-stage biotech (Nasdaq: PRTA) developing monoclonal antibodies for neurodegenerative diseases including Alzheimer's and Parkinson's. Therini CEO Tara Nickerson was previously CBO at Prothena. Same biologic modality and disease focus.
- AC Immune: Clinical-stage biotech developing immunotherapies for neurodegenerative diseases, particularly Alzheimer's disease. Therini's CMO Neurology Nuno Mendonça was previously CMO at AC Immune. Highly comparable therapeutic approach and indication focus.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases, leveraging insights into neurodegeneration biology. Comparable modality (biologics), target indications (AD, Parkinson's), and clinical stage.
- Annexon Biosciences: Clinical-stage biotech developing complement-targeted therapeutics for neurodegenerative and autoimmune diseases. Comparable clinical stage, biologics approach, and CNS disease focus.
- Kodiak Sciences: Clinical-stage biotech developing novel therapeutics for retinal diseases. Therini CMO Ophthalmology Joel Naor was previously VP at Kodiak through its IPO. Same retinal disease focus and biologic modality.
Broad incumbents
- Roche: Global pharmaceutical incumbent with major Alzheimer's programs (gantenerumab) and a leading ophthalmology franchise (Lucentis, faricimab). Broad incumbent with overlapping indications though not specialized in the fibrin-targeting niche.
- Eli Lilly: Global pharmaceutical incumbent with approved anti-amyloid AD therapy (Kisunla/donanemab) and an investor/lab-partner relationship with Therini via Gateway Labs. Major established player in Therini's primary indication.
- Eisai: Global pharmaceutical incumbent with leading AD franchise (Leqembi/lecanemab, co-developed with Biogen). Broad incumbent operating in Therini's primary indication with established commercialization infrastructure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Therini Bio social profiles
Digital presenceTherini Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Therini Bio leadership team
Management profileNumber of profiles
Profiles11 records
Therini Bio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Therini Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Therini Bio
What does Therini Bio do?
Therini Bio is developing a clinical-stage pipeline of fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. The company's lead candidate THN391 is a first-in-class humanized monoclonal antibody that selectively blocks the inflammatory epitope of fibrin without affecting coagulation, being advanced through Phase 1b trials for Alzheimer's Disease and Diabetic Macular Edema. The pipeline also includes THN622, a bispecific antibody combining anti-fibrin and anti-VEGF mechanisms for retinal conditions.
Is Therini Bio a public or private company?
Therini Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Therini Bio founded?
Therini Bio was founded in 2019. It employs 1 to 10 people.
Where is Therini Bio based?
Therini Bio is headquartered in San Francisco, United States, in the North America region.
How does Therini Bio make money?
One revenue line is on record: biopharmaceutical Product Revenue.
Who are Therini Bio's main competitors?
Direct peers on record are Opthea Limited, Alector, Prothena Corporation, AC Immune, Denali Therapeutics, Annexon Biosciences and Kodiak Sciences. Broad incumbents are Roche, Eli Lilly and Eisai.
Does Therini Bio have an API?
No public API is recorded for Therini Bio.
What industry is Therini Bio in?
Therini Bio's product category is Neuroscience Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 334510 and its SIC code is 2834.